1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 123,00 | 128,00 | 05.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Belite Bio stock price target raised to $187 from $132 at Benchmark | 2 | Investing.com | ||
| Di | Mizuho upgrades Belite Bio stock to Outperform on positive trial data | 1 | Investing.com | ||
| Di | Mizuho stuft Belite Bio nach positiven Studiendaten auf 'Outperform' hoch | 5 | Investing.com Deutsch | ||
| Di | Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering | 2 | Seeking Alpha | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| Di | Belite Bio prices public offering of ADSs at $154 each | 1 | Investing.com | ||
| Di | Belite Bio, Inc: Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) | ||
| Di | Why Belite Bio Stock Soared on Monday | 1 | The Motley Fool | ||
| 01.12. | Belite Bio kündigt Kapitalerhöhung an - Aktie gibt nach | 2 | Investing.com Deutsch | ||
| 01.12. | Belite Bio launches public offering of American Depositary Shares | 1 | Investing.com | ||
| 01.12. | Belite Bio announces proposed underwritten public offering of ADSs | 1 | Seeking Alpha | ||
| 01.12. | Belite Bio, Inc: Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) | ||
| 01.12. | Belite continues ascent as Stargardt drug hits mark in late-stage trial | 2 | BioPharma Dive | ||
| 01.12. | Belite Bio Reports Landmark Phase 3 Success For Tinlarebant In Stargardt Disease | - | RTTNews | ||
| 01.12. | Belite brings FDA filing into view with phase 3 Stargardt disease victory | 1 | FierceBiotech | ||
| 01.12. | Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease | 1 | Benzinga.com | ||
| 01.12. | Belite plans filing for oral Stargardt drug after phase 3 win | 1 | pharmaphorum | ||
| 01.12. | Belite Bio's tinlarebant shows 36% reduction in Stargardt disease lesions | 1 | Investing.com | ||
| 01.12. | Belite Bio meldet Erfolg in Phase-3-Studie: Tinlarebant reduziert Läsionen bei Morbus Stargardt um 36 % | 2 | Investing.com Deutsch | ||
| 01.12. | Belite Bio, Inc: New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease | 2 | GlobeNewswire (USA) | ||
| 01.12. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,430 | +1,15 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen | |
| ARGENX | 770,40 | -0,52 % | argenx SE: argenx Announces Results of Extraordinary General Meeting of Shareholders | November 18, 2025 - 10:01 PM CET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,460 | -2,01 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 7,630 | -0,91 % | Quanterix Corporation Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 9,340 | +2,75 % | Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target | ||
| PRAXIS PRECISION MEDICINES | 247,99 | +30,54 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,900 | +5,37 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,770 | -1,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | ||
| ARCUTIS BIOTHERAPEUTICS | 31,200 | +0,13 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| NUVALENT | 109,60 | +2,56 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,63 | +0,13 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| QIAGEN | 40,405 | -0,02 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,850 | -1,29 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 127,00 Euro und damit -0,78 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.